The mission of the Sidney Kimmel Cancer Center (SKCC) is to leverage research expertise to reduce the overall incidence, burden, and mortality from cancer in Greater Philadelphia and beyond. SKCC goals are realized through unique strengths in addressing cancer problems through collaboration across basic, clinical, and population research disciplines. As a matrixed, consortium cancer center, SKCC leverages the intellectual strength of discoveries of members at Thomas Jefferson University (TJU), Drexel University (DU) Schools of Medicine and Public Health, and Lankenau Institute for Medical Research (LIMR). Expertise is clustered into five major Research Programs, two of which are Discipline-Based Programs and three of which are Disease-Oriented Programs. A notable feature of SKCC Programs is that each is comprised of highly integrated basic, clinical, and population researchers, working together on research areas that address the cancer-associated needs of the catchment area. This is an intentional structure that further blossomed under the guidance of new SKCC leadership and the revitalized External Advisory Board (EAB). Given the health research and care focus of the parent university (TJU), this mechanism of Program integration mirrors the strong translational focus and interdisciplinary nature of the organization. SKCC utilizes the TIPS (Transdisciplinary Integration of Population Science) mechanism as a highly specialized, cross-cutting organizational structure that has the benefit of allowing population scientists to remain programmatically integrated into Programs with basic and clinical researchers, as well as providing a platform for cultivating new population oriented strategies that can be deployed across all Programs. Thematic working groups also exist that link subspecialties across Programs, in addition to Shared Resources that provide exceptional expertise, services, and technologies required for leading edge investigation and high scientific impact. Under the new Director, Dr. Knudsen (appointed January 2015), SKCC sharpened focus on addressing catchment area needs, nurtured transdisciplinary research, expanded research capabilities, extended outreach and clinical research into the community, and enhanced the pace of bench-to-bedside discovery. The roadmap for the SKCC mission is paved by a strategic plan deemed IMPACT, developed by Dr. Knudsen and highly engaged SKCC Leaders. Under Dr. Knudsen?s leadership, SKCC increased: membership, the pace and breadth of impactful discovery, bench-to-bedside translation, clinical trial activity, cancer-focused funding, capacity to address the cancer needs of the catchment area, and the overall impact of the Center. Current aims are to: 1) Discover the molecular basis of cancer development & progression in diverse populations through integration of basic, population, and clinical research; 2) Develop knowledge into effective new prevention, detection, and treatment strategies for cancer, emphasizing catchment area needs; 3) Disseminate through patient education and training of laboratory-based, population, and clinical scientists; 4) Deliver and enhance access to the most advanced cancer care.
The overarching goal of the Sidney Kimmel Cancer Center (SKCC) is to leverage research expertise to reduce the overall incidence, burden, and mortality from cancer in Greater Philadelphia and beyond. SKCC goals are realized through unique strengths in addressing cancer problems through collaboration across basic, clinical, and population research disciplines. SKCC is nucleated at Thomas Jefferson University (TJU) and enriched by fully integrated research consortium partners from Drexel University (DU)'s School of Medicine and School of Public Health and the Lankenau Institute for Medical Research (LIMR); building on these strengths, SKCC focuses on addressing catchment area needs through nurturing transdisciplinary research, expanding innovative research capabilities, extending outreach and clinical research into the community, and enhancing the pace of bench-to-bedside discovery.
|Vido, Michael J; Le, Kaitlyn; Hartsough, Edward J et al. (2018) BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association. Cell Rep 25:1501-1510.e3|
|Brody, Jonathan R; Dixon, Dan A (2018) Complex HuR function in pancreatic cancer cells. Wiley Interdiscip Rev RNA 9:e1469|
|Liao, Lili; Liu, Zongzhi Z; Langbein, Lauren et al. (2018) Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer. Elife 7:|
|Heeke, Arielle L; Pishvaian, Michael J; Lynce, Filipa et al. (2018) Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precis Oncol 2018:|
|Parent, Kristin N; Schrad, Jason R; Cingolani, Gino (2018) Breaking Symmetry in Viral Icosahedral Capsids as Seen through the Lenses of X-ray Crystallography and Cryo-Electron Microscopy. Viruses 10:|
|Rappaport, Jeffrey A; Waldman, Scott A (2018) The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia. Front Oncol 8:299|
|Pandya, Kalgi D; Palomo-Caturla, Isabel; Walker, Justin A et al. (2018) An Unmutated IgM Response to the Vi Polysaccharide of Salmonella Typhi Contributes to Protective Immunity in a Murine Model of Typhoid. J Immunol 200:4078-4084|
|Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999|
|Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337|
|Meyer, Sara E; Muench, David E; Rogers, Andrew M et al. (2018) miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med 215:2115-2136|
Showing the most recent 10 out of 807 publications